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Abstract
Background: After many years of neglect, schistosomiasis control is going to scale. The strategy of choice is preventive
chemotherapy, that is the repeated large-scale administration of praziquantel (a safe and highly efficacious drug) to at-risk
populations. The frequency of praziquantel administration is based on endemicity, which usually is defined by prevalence
data summarized at an arbitrarily chosen administrative level.
Methodology: For an ensemble of 29 West and East African countries, we determined the annualized praziquantel
treatment needs for the school-aged population, adhering to World Health Organization guidelines. Different administrative
levels of prevalence aggregation were considered; country, province, district, and pixel level. Previously published results on
spatially explicit schistosomiasis risk in the selected countries were employed to classify each area into distinct endemicity
classes that govern the frequency of praziquantel administration.
Principal Findings: Estimates of infection prevalence adjusted for the school-aged population in 2010 revealed that most
countries are classified as moderately endemic for schistosomiasis (prevalence 10–50%), while four countries (i.e., Ghana,
Liberia, Mozambique, and Sierra Leone) are highly endemic (.50%). Overall, 72.7 million annualized praziquantel
treatments (50% confidence interval (CI): 68.8–100.7 million) are required for the school-aged population if country-level
schistosomiasis prevalence estimates are considered, and 81.5 million treatments (50% CI: 67.3–107.5 million) if estimation is
based on a more refined spatial scale at the provincial level.
Conclusions/Significance: Praziquantel treatment needs may be over- or underestimated depending on the level of spatial
aggregation. The distribution of schistosomiasis in Ethiopia, Liberia, Mauritania, Uganda, and Zambia is rather uniform, and
hence country-level risk estimates are sufficient to calculate treatment needs. On the other hand, countries like Burkina
Faso, Mali, Mozambique, Sudan, and Tanzania show large spatial heterogeneity in schistosomiasis risk, which should be
taken into account for calculating treatment requirements.
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Introduction
Schistosomiasis is a snail-borne parasitic disease, which affects
more than 200 million people globally based on 2003 population
estimates [1]. The main burden is concentrated in sub-Saharan
Africa, where schistosomiasis control had been neglected for many
decades, and hence country-specific infection rates above 25% are
the norm rather than the exception [1–3].
The global strategy for the control of schistosomiasis, as
recommended by the World Health Organization (WHO), is
preventive chemotherapy, that is the repeated, large-scale
administration of the antischistosomal drug praziquantel to at-
risk populations [4]. Because school-aged children are at highest
risk of schistosome infection, preventive chemotherapy is primarily
targeted at this population group. The frequency of treatment
depends on the level of endemicity, defined as low (prevalence
,10%), moderate (10–50%), and high (.50%) based on WHO
thresholds [4,5]. Classification into one of these categories should
be done according to schistosomiasis prevalence estimates among
the school-aged population. In practice, estimates of schistosomi-
asis and other helminth infection are often based on old survey
data and/or very sparse geographical data. However, historical
data are largely obsolete due to ongoing control efforts, ecological
transformations, demographic changes, and improved hygiene,
among other reasons, while sparse geographical data are not
representative for large areas [1,6–9]. In addition, most prevalence
estimates lack empirical modeling, which is mandatory to obtain
accurate averages of the risk of infection over large geographical
regions, taking into account spatial heterogeneity. Even though
WHO treatment guidelines are valuable tools to plan and conduct
preventive chemotherapy programs, it remains unclear at which
geographical scale or other stratifications (e.g., ecological zones)
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the level of endemicity should be defined to avoid unnecessary
treatments, increase cost-effectiveness, and meet local needs.
The aim of this paper was to assess the effect of the geographical
scale of schistosomiasis risk estimates on the amount of
praziquantel treatment needed in the school-aged population in
selected parts of Africa. In contrast to existing treatment need
calculations based on crude country prevalence estimates [10], we
used spatially explicit, model-based schistosomiasis risk estimates
at high spatial resolution [2,3]. Our modeling framework includes
uncertainty measures, and hence allows confidence intervals (CIs)
to be determined around predicted treatment needs. These
empirical estimates are able to capture potential small transmission
hotspots within a country that are typical for schistosomiasis, as the
disease is often focally distributed [11,12], and facilitate spatial
aggregation of schistosomiasis risk at different geographical scales.
In our analysis, we focus on differences in the total amount of
required treatments when risk estimates are known at country,
regional, district, or pixel level.
Methods
Schistosomiasis Risk Estimates
In our previous work, we determined the spatial distribution of
Schistosoma haematobium and S. mansoni in an ensemble of 29 West
and East African countries at a spatial resolution of 565 km [2,3].
We used a geostatistical modeling approach, applied to survey
data extracted from the Global Neglected Tropical Disease
database (http://www.gntd.org) [13]. Statistical relations of
Schistosoma prevalence with climatic and other environmental
factors were used to obtain model-based predictions at unobserved
locations using country-level joint posterior distributions. The
median and 50% CIs of the joint posterior distributions were
utilized for further analyses.
The risk predictions of Schur and colleagues were originally
summarized as country-specific Schistosoma infection prevalence
estimates adjusted for individuals aged #20 years in 2010 [2,3].
For the current analysis, these data were re-adjusted to the school-
aged population (children aged between 5 and 14 years), in line
with the WHO definition of the school-aged child [14].
Population Data
Population count data at 161 km spatial resolution in Africa for
2008 were obtained from the LandScan global population
database (http://www.ornl.gov/landscan/). Country-specific rates
of annual change in population during the period of 2005–2010
were extracted from the United Nations World Population
Prospects [15]. Estimates on the percentage of children aged
between 5 and 14 years among the total population per country
were obtained from the Population Division, provided by the
international database of the United States Census Bureau [16].
Population estimates of 2008 were projected to 2010 taking into
account estimates of annual population change, readily adjusted to
school-aged children. These estimates were then converted to a
565 km resolution grid using the geographical information system
(GIS) software ArcMap version 9.2 (ESRI) to match the spatial
resolution of the geostatistical schistosomiasis risk estimates for
West and East Africa.
Data Aggregation by Administrative Zone
National preventive chemotherapy programs are usually imple-
mented at specific administrative levels, for example at country,
province, and district level. Shape files containing geographical
information on the administrative boundaries of these levels were
downloaded from the Map Library (http://www.maplibrary.org)
for our ensemble of 29 West and East African countries. These
files were linked in ArcMap with schistosomiasis risk estimates and
school-aged population to estimate the number of infected
children at pixel-level.
Population-adjusted prevalence at a given administrative region
was calculated by summing all infected school-aged children at
pixel-level and dividing by the total school-aged population in that
region. This calculation takes into account that pixels are not
equally populated, and hence do contribute to the area-specific
prevalence in the same way.
Calculation of Praziquantel Treatment Needs
The aggregated and pixel-level data on the school-aged children
and population-adjusted prevalence were converted to the
required amount of drugs per year (‘‘annualized treatment needs’’)
using WHO schistosomiasis control guidelines [4,5]. These
guidelines suggest different treatment strategies according to
endemicity thresholds. High endemicity is defined by prevalence
of at least 50% among school-aged children using parasitological
diagnostic tests. Low and moderate endemicity settings are
classified by prevalence levels of ,10% and 10–50%, respectively.
For high endemicity areas, annual treatment of all school-aged
children (and other high-risk groups, e.g., fishermen) is proposed.
With regard to treatment needs in the school-aged population, we
therefore estimated the amount of annualized praziquantel
treatment needs in these areas to be equal to the number of
school-aged children. In areas with moderate endemicity, it is
recommended to treat school-aged children every other year.
Hence, we consider half of the school-aged population for annual
praziquantel treatment in our calculation of annualized needs.
Areas of low endemicity warrant treatment of school-aged children
twice during primary schooling (on entry and just before leaving
school). Assuming an average duration of 6 years in primary
school, we estimate annualized praziquantel needs by considering
one third of the school-aged population for treatment every year.
Author Summary
More than 200 million people are affected by the snail-
borne disease schistosomiasis. The main strategy to
control schistosomiasis is to regularly treat school-aged
children with the drug praziquantel. The frequency of
praziquantel treatment depends on the average preva-
lence of schistosomiasis, which can be defined as low
(prevalence ,10%), moderate (10–50%), or high (.50%).
However, it remains unclear at which geographical scale
these prevalence levels should be considered to avoid
unnecessary treatments but still comply with local needs.
We investigated the effect of the geographical scale for an
ensemble of 29 West and East African countries using
previously published model-based schistosomiasis risk
estimates obtained at high spatial resolution. These
estimates allow spatial risk aggregation at different
geographical scales (i.e., country, region, district, or pixel
level). More than 70 million praziquantel treatments are
required every year for school-aged children if country-
level estimates are used. On a more refined geographical
scale (i.e., province), annualized praziquantel treatments
increase by 12%. Depending on the averaged schistoso-
miasis prevalence and the spatial risk variation across a
country, the difference in the estimated amount of
praziquantel between country-level aggregation and other
geographical scales might be very important, as for
example in Burkina Faso, Ghana, and Mali.
Modeling Schistosomiasis Treatment Needs
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Results
Country-Specific Schistosomiasis Risk and Endemicity
Classes
Country-specific estimates on the prevalence of schistosomiasis
among the school-aged population and the number of infected
school-aged children are summarized in Table 1. The population-
adjusted prevalence estimates revealed that 30.2 and 19.5 million
school-aged children in West and East Africa, respectively, are
infected with S. haematobium, S. mansoni, or both species concur-
rently. At the unit of the country, we found infection prevalence
ranging between 14.4% (The Gambia) and 60.2% (Liberia) with a
mean country-prevalence of 37.3%. Most countries were classified
as moderately endemic (prevalence 10–50%), whereas four
countries (i.e., Ghana, Liberia, Mozambique, and Sierra Leone)
were considered as highly endemic (.50%). Figure 1A displays the
schistosomiasis endemicity aggregated at country-level and
Figure 1B the spatial distribution of schistosomiasis risk over
Africa based on current WHO endemicity thresholds. High- and
low-risk areas are found in West and East Africa. Most low-risk
areas are located in Cameroon, Saharan Mali, Mauritania, Niger,
and parts of Ethiopia, Kenya, Uganda, and Zambia. Large high-
risk regions are found along the Niger River, in Ghana, Liberia,
Mozambique, and Sierra Leone.
Annualized Praziquantel Treatment Needs
Table 1 summarizes the estimated amount of annualized
praziquantel treatment needs, stratified by country, based on
different administrative levels of risk estimates, i.e., country,
province, district, and pixel level, using WHO thresholds. Table 2
shows the respective 50% CIs. Overall, in West and East Africa,
72.7 million treatments (50% CI: 68.8–100.7 million) are required
if calculations are based on schistosomiasis risk estimates at
country level. An additional 8.8 million treatments (resulting in a
total of 81.5 million treatments, 50% CI: 67.3–107.5 million) are
needed if the calculation is based on province-level risk estimates.
Calculations employing risk estimates at higher level of disaggre-
gation – at district or pixel level – result in a total amount of 82.7
million (50% CI: 66.0–111.1 million) and 83.0 million (50% CI:
61.0–119.8 million) treatments, respectively.
Over 5 million annual praziquantel treatments for the school-
aged population are required in Ethiopia, Ghana, and Nigeria,
while less than half a million treatments are needed for preventive
chemotherapy in Djibouti, Eritrea, The Gambia, Guinea-Bissau,
and Mauritania. These calculations are based on country-wide risk
estimates and they vary when risk estimates are available at higher
level of disaggregation.
Considering treatment in entire communities in high endemicity
areas and 20% of the non-school-aged population in moderately
endemic areas (as recently considered by WHO [17]), the required
annual amount of praziquantel increases to more than 170 million
or almost 235 million treatments using country- or pixel-level risk
estimates, respectively (results not presented in Table 1).
Country Examples
Next, selected country examples are given regarding annualized
praziquantel treatment needs in the school-aged population. These
examples highlight that the required amount of praziquantel
depends on the level of aggregation of the schistosomiasis risk
estimates, and is particularly pronounced in countries where the
distribution of schistosomiasis shows high focality.
Ghana. Figure 2A displays endemicity classes based on
population-adjusted prevalence of school-aged children at prov-
ince level (called regions) throughout Ghana. The estimated
prevalence in the Upper West and Volta regions is below the 50%
threshold, even though Ghana was estimated to have an overall
high endemicity of schistosomiasis with an average country-
specific prevalence of 54.6%. Figures 2B and 2C show the
endemicity classes at district and pixel level, respectively.
Moderate levels of endemicity are found in some districts in the
northeast, centre, and southeast of the country. A map of the
spatial distribution of schistosomiasis infection risk at pixel level is
given in Figure 2D. The lowest prevalence of 12.1% was detected
in Ketu district of the Volta region (southeast Ghana) close to the
border with Togo. The highest prevalence of 90.0% was found in
the Sunyani and Wenchi districts of the Brong-Ahafo region
(middle-western part of Ghana). Estimated amounts of annualized
treatment needs for the school-aged population would be reduced
from 5.4 million (50% CI: 2.7–5.4 million) to 4.7 million (50% CI:
2.7–5.4 million) when prevalence is aggregated at province- rather
than country-level. The amount of treatments could be further
reduced when aggregation is carried out at district level (4.6
million, 50% CI: 2.7–5.4 million) or pixel level (4.5 million, 50%
CI: 2.7–5.4 million).
Burkina Faso. Endemicity classes at province (called regions)
and district level (called provinces) in Burkina Faso are shown in
Figures 3A and 3B, respectively. The overall country-specific
prevalence in school-aged children was 48.0%, indicating moder-
ate endemicity. However, five regions in Burkina Faso (i.e.,
Centre, Centre-North, East, Nord, and Sahel) are highly endemic,
as well as 20 (out of 45) communes. The endemicity-class map at
pixel level (Figure 3C) further highlights that large parts of the
country, especially in north-east and smaller areas in the south, are
highly endemic, while a tiny part of the Hauts-Bassins region in
Ke´ne´dougou province is classified as low-endemic. Figure 3D
provides more details on the estimated spatial distribution of
schistosomiasis risk throughout Burkina Faso, which varies from
9.0% to 87.5%. Annualized treatment needs would increase from
about 2.0 million (50% CI: 2.0–4.1 million) to 2.9 million (50%
CI: 2.2–4.0 million) with higher level aggregation of prevalence
estimates (from country to province level) and remain at 3.0
million for both district and pixel level estimates (50% CI: 2.2–4.1
million and 2.1–4.1 million, respectively).
Zambia. The estimated country-specific prevalence of schis-
tosomiasis in school-aged children in Zambia is 25.9%, which
classifies the country as moderately endemic. A switch from
country to province level revealed no changes in endemicity class
(Figure 4A). However, at district-level (Figure 4B), Luwingo and
Mporokoso (located in the north-east) are low-endemic, while the
Chama, Chililabombwe, and Lundazi districts (in the east and
centre-north) show high endemicity. Figures 4C and 4D show the
distribution of endemicity classes and schistosomiasis risk in
Zambia at pixel-level, respectively. The risk was estimated
between 2.0% and 99.6%. Low-endemic areas are found in
northern Zambia, covering about 2506250 km. Smaller low
endemicity areas are located in the centre of the country. Highly
endemic regions are distributed throughout Zambia with some
larger clusters in the North and East. The estimated annualized
treatment needs are between 1.1 and 1.2 million with only little
effect of the aggregation level of schistosomiasis prevalence.
Senegal. Among the 29 countries included in the current
analysis, Senegal has the second lowest national schistosomiasis
prevalence in school-aged children (18.2%; moderately endemic).
Figure 5A shows that the Dakar and Thie`s regions (province level)
have low endemicity, while the remaining regions are moderately
endemic. District level (Figure 5B) and pixel level (Figure 5C) maps
indicate that areas of low endemicity expand from the West of
Senegal toward the North. Some areas are classified as highly
Modeling Schistosomiasis Treatment Needs
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endemic, mainly in the East. The spatial distribution of
schistosomiasis risk over Senegal varies from 0.5% (region of
Thie`s) to 89.3% (Tambacounda department in the Tambacounda
region, central Senegal) as shown in Figure 5D. About 1.6 million
praziquantel treatments (50% CI: 1.6–1.6 million) are required
yearly according to population-adjusted schistosomiasis prevalence
estimated at country-level. An estimated 1.4 million treatments are
needed based on province- or district-based data aggregation (50%
CI: 1.4–1.5 million and 1.3–1.5 million, respectively). According
to pixel-based approaches, there are an estimated 1.5 million
treatments (50% CI: 1.3–1.8 million) needed every year.
Effect of Changing Thresholds
There are ongoing discussions within WHO and other
organizations and consortia whether the threshold to separate
between moderate and heavy schistosomiasis endemicity should be
halved from 50% to 25%. Of note, the lower threshold is already
adopted by the Schistosomiasis Consortium for Operational
Research and Evaluation (SCORE) in the frame of large-scale
programs that aim at gaining (prevalence $25%) and sustaining
(prevalence 10–24%) schistosomiasis control (http://score.uga.
edu/Projects.html). This new 25% threshold would imply that
more than 120 million annualized praziquantel treatments (50%
CI: 122.4–131.5 million) would be needed in the 29 African
countries for the school-aged population alone when considering
country-level prevalence estimates, and around 112 million
treatments based on aggregations at other administrative levels
(see Tables 1 and 2). A change in the threshold would not affect all
countries in the same way, e.g., the estimated total praziquantel
treatment needs in The Gambia (with an averaged population-
adjusted prevalence of 14.4%), Ghana (54.6%), Mozambique
(58.5%), Sierra Leone (59.3%), and Liberia (60.2%) would remain
almost the same, irrespective of the level of aggregation, while it
would increases by more than 50% in Rwanda (33.5%), Sudan
(34.7%), Burundi (38.1%), Somalia (38.7%), and Malawi (47.4%)
based on prevalence aggregations at district-level.
Discussion
Preventive chemotherapy is the current mainstay for morbidity
control due to schistosomiasis and other helmintic diseases
[4,9,14,18–20]. The administration of praziquantel to high-risk
communities, most importantly school-aged children, is often
based on crude Schistosoma prevalence estimates that are aggre-
gated at an arbitrarily chosen administrative level. Our analysis
shows that the geographical scale at which schistosomiasis
prevalence data are aggregated affects the estimated amount of
treatment needs, and hence has to be considered in the calculation
of the number of praziquantel treatments required for national
schistosomiasis control programs.
Contrary to what we expected, the total amount of praziquantel
treatments is higher at a smaller administrative unit of schistoso-
miasis prevalence aggregation (i.e., district level versus province or
country level). For example, we estimate that the annualized
praziquantel treatment needs for the school-aged population are
more than 10% higher in the ensemble of 29 West and East
African countries considered here when calculated using district
instead of country level prevalence estimates. This observation can
be explained because many East and West African countries had a
prevalence of schistosomiasis in school-aged children at around
40% (moderately endemic situation), and the infection risk is not
uniformly distributed throughout a country. Indeed, some
province or district specific prevalence estimates were above the
50% threshold suggested by WHO, and hence warrant annual
treatment rather than treatment every second year for moderate
Figure 1. Endemicity estimates of schistosomiasis for an ensemble of 29 West and East African countries. The endemicity levels at
country-level (A) and pixel-level (B) are based on previously published geostatistical model-based prevalence estimates [2,3] and WHO classifications
[4,5]. Low endemicity is defined as schistosomiasis prevalence in school-aged children ,10%, moderate endemicity as prevalence between 10% and
50%, and high endemicity as prevalence .50%.
doi:10.1371/journal.pntd.0001773.g001
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endemicity areas (prevalence 10–50%). We rarely observed
switches from moderate to low endemicity levels. Such switches
are expected to occur in countries where the overall prevalence of
Schistosoma infection is close to 10%. Such low prevalence levels
were only found in The Gambia (14.4%) and Senegal (18.2%). In
countries currently classified as highly endemic, the required
amount of treatment per year will be reduced if schistosomiasis
prevalence is calculated at province or even district level, as some
areas will fall under the 50% threshold.
Utzinger et al. (2009) [10] estimated that 91.3 million
praziquantel treatments are needed for the school-aged population
based on risk estimates aggregated at country level with 2006
population data for the 29 East and West African countries
considered here. This is almost 20 million more than the 72.7
million treatments estimated in the current study. What are the
reasons for this difference? Most importantly, there are marked
differences in the country prevalence estimates of schistosomiasis
leading to different classifications of endemicity (e.g., Burkina
Faso, Mali, and Tanzania). Utzinger and colleagues employed
prevalence estimates published in Steinmann et al. (2006) [1],
which are to a large extent based on data obtained before 1989.
However, due to major demographic and ecological transforma-
tions (e.g., urbanization), social and economic development, and
implementation of schistosomiasis control programs, country
prevalence estimates have changed (mostly to lower levels).
Moreover, different sources of population data and the estimated
percentage of school-aged children have some leverage on the
estimated annualized praziquantel treatment needs.
In early 2012, WHO released new estimates on the total
number of individuals requiring preventive chemotherapy with
Figure 2. Schistosomiasis endemicity estimates at different administrative levels and pixel-level prevalence in Ghana. Provincial (A),
district (B), and pixel-level (C) endemicity and pixel-level prevalence (D). The country-specific prevalence in Ghana is 54.6% based on previously
published geostatistical model-based estimates [2,3]. Low (schistosomiasis prevalence in school-aged children ,10%), moderate (10–50%), and high
(.50%) endemicity levels are based on WHO guidelines [4,5].
doi:10.1371/journal.pntd.0001773.g002
Figure 3. Schistosomiasis endemicity estimates at different administrative levels and pixel-level prevalence in Burkina Faso.
Provincial (A), district (B), and pixel-level (C) endemicity and pixel-level prevalence (D). The country-specific prevalence in Burkina Faso is 48.0% based
on previously published geostatistical model-based estimates [2,3]. Low (schistosomiasis prevalence in school-aged children ,10%), moderate (10–
50%), and high (.50%) endemicity levels are based on WHO guidelines [4,5].
doi:10.1371/journal.pntd.0001773.g003
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praziquantel [17]. For Africa (using WHO country classifications;
e.g. Sudan being part of the Eastern Mediterranean rather than
Africa), it is estimated that as many as 102 million treatments are
needed for the school-aged population and 221 million treatments
when including communities in high and moderately endemic
areas. Of note, secondary administrative level schistosomiasis risk
estimates were employed to define endemicity levels. The bulk of
these risk estimates lacks geostatistical modeling and neglects
potential spatial correlation inherent to the data. Moreover, in the
absence of recent data, information was also obtained from surveys
conducted before 1989 without accounting for changes in
prevalence levels over time. Compared to the WHO treatment
needs calculations for the school-aged population, our estimates
are by approximately 30 million annual treatments smaller, but we
used a different set of African countries in the current analysis. For
the missing African countries we used the previously published
country-level prevalence estimates [10] to calculate the total
treatment needs in the school-aged population. This assumption
would result in an annualized amount of 105.9 million
praziquantel treatments per year in school-aged children. Inter-
estingly, this estimate is very close to the 102 million put forth by
WHO [17].
Several issues warrant discussion regarding our geostatistical
model-based analysis and its implication for preventive chemo-
therapy. First, human, financial, and technical resources for the
control of neglected tropical diseases, including schistosomiasis,
have increased considerably in recent years [21,22]. New
initiatives and partnerships aim to bring praziquantel distribution
to scale, such as the Schistosomiasis Control Initiative (SCI) [19]
and the Global Network for Neglected Tropical Diseases (http://
Figure 4. Schistosomiasis endemicity estimates at different administrative levels and pixel-level prevalence in Zambia. Provincial (A),
district (B), and pixel-level (C) endemicity and pixel-level prevalence (D). The country-specific prevalence in Zambia is 25.9% based on previously
published geostatistical model-based estimates [2,3]. Low (schistosomiasis prevalence in school-aged children ,10%), moderate (10–50%), and high
(.50%) endemicity levels are based on WHO guidelines [4,5].
doi:10.1371/journal.pntd.0001773.g004
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www.globalnetwork.org/) [10]. It is therefore conceivable that the
overall schistosomiasis prevalence in some areas might have
dropped from high to moderate, and from moderate to low
endemicity thresholds, which would result in fewer treatments
required. However, rapid re-infection after de-worming is a
common phenomenon, which challenges the control of schistoso-
miasis [23] and other helminth infections [24,25], and hence has
to be considered when reducing the frequency of treatment
campaigns. Some experts are currently discussing to lower the
threshold distinguishing between moderate and high endemicity
from 50% to 25% to further reduce morbidity and this strategy
might also have an impact on transmission. However, such a move
would strongly increase the required amount of annualized
treatment needs for the school-aged population from 72.7 million
to more than 120 million for the 29 West and East African
countries considered here.
Our praziquantel treatment needs were calculated based on
schistosomiasis risk estimates summarized at different scales.
Administrative boundaries were used because large-scale preven-
tive chemotherapy programs are usually planned and conducted at
specific administrative levels (e.g., district). However, given the
strong focality of schistosomiasis, there is strong heterogeneity
within administrative boundaries. For instance, villages in close
proximity to freshwater bodies, where intermediate host snails
proliferate, are often highly endemic for schistosomiasis, while
villages farther away (but in the same administrative region) might
have prevalence levels below 10%, even though the overall
endemicity in the considered administrative unit is moderate.
Hence, stratification of areas should preferably be based on the
geography and suitable freshwater bodies (e.g., ecozones), which is
the recommended strategy by WHO [4]. However, many
schistosomiasis data are not (yet) available at geographically
stratified locations, but are instead aggregated over administrative
levels. This makes it difficult for local health managers to
implement preventive chemotherapy programs considering the
environment. In addition, stratification of the area according to
Figure 5. Schistosomiasis endemicity estimates at different administrative levels and pixel-level prevalence in Senegal. Provincial (A),
district (B), and pixel-level (C) endemicity and pixel-level prevalence (D). The country-specific prevalence in Senegal is 18.2% based on previously
published geostatistical model-based estimates [2,3]. Low (schistosomiasis prevalence in school-aged children ,10%), moderate (10–50%), and high
(.50%) endemicity levels are based on WHO guidelines [4,5].
doi:10.1371/journal.pntd.0001773.g005
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the environment is more complex since multiple ecological factors
may interact.
Large parts of Africa are co-endemic for several neglected
tropical diseases [26–29]. This is explained by similar pathways of
infection and lack of preventive measures [30,31]. Hence, efforts
should be made to integrate control programs so that multiple
neglected tropical diseases can be addressed in order to reduce co-
morbidity and costs. The morbidity of up to seven neglected
tropical diseases might be addressed by preventive chemotherapy
with four drugs, which can be safely co-administered based on the
current state of knowledge [18,32,33]. However, with decreasing
level of co-infection risk due to reduced prevalence, co-adminis-
tration of multiple drugs becomes less cost-effective and many
individuals will be treated unnecessarily with multiple drugs
[34,35]. This potentially increases the risk of drug resistance
development.
Considering that, on average, three tablets of praziquantel are
needed to treat a school-aged child for schistosomiasis, more than
210 million tablets would need to be administered every year to
this population group in the 29 East and West African countries
considered here. The distribution of such large amounts of
praziquantel is a formidable challenge, especially in remote rural
areas. It will require strong health systems and good supply
strategies, which are currently lacking in large parts of Africa.
Even though the price of a single tablet of praziquantel is now
below US$ 0.10 [36,37] and pharmaceutical companies have
pledged new donations, the costs for drug storage and distribution
are considerable. Additionally, it might be hard to achieve high
compliance after several rounds of preventive chemotherapy,
because morbidity is likely to be reduced and individuals might
refuse to take the drugs when feeling healthy.
With the transition from morbidity control to transmission
control of schistosomiasis and other helminthic diseases, preven-
tive chemotherapy alone is unlikely to achieve this goal [38,39].
Complementary measures will be required depending on the
setting and available resources. For instance, the ‘‘Tokomeza
Kichocho’’ project is aiming to eliminate schistosomiasis from
Zanzibar based on a multi-pronged approach, i.e., preventive
chemotherapy targeting school-aged children, intermediate host
snail control, improved access to sanitation, water and hygiene,
and formative health education to change human behavior.
In conclusion, the geographical scale to estimate schistosomiasis
risk should take into consideration the expected country-specific
prevalence level and the diversity of schistosomiasis risk in the
country in order to accurately calculate praziquantel treatment
needs. In countries with rather homogeneous schistosomiasis
distribution, it would be sufficient to implement control strategies
based on schistosomiasis prevalence aggregated at country level.
However, in countries with a highly focal distribution of
schistosomiasis, province- or even district-level calculations of
prevalence have to be considered in order to provide sufficient
amounts of treatments to those at risk of morbidity and to reduce
the costs in areas requiring less frequent rounds of preventive
chemotherapy. The work reported here can be readily adapted to
other neglected tropical diseases that have also endorsed
preventive chemotherapy as the strategy of choice for morbidity
control. In addition, it will be interesting to repeat our analysis in
the frame of ongoing large-scale control programs, which are
constantly changing prevalence levels and disease, and hence
treatment needs.
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